Will AbbVie’s $10.9 Billion Acquisition Shape Its Dividend?
AbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
New investors in 2023 must understand the current market landscape. Familiarize yourself with essential tips and strategies to thrive in investing.
28,353 articlesAbbVie just agreed to buy Apogee Therapeutics for $10.9 billion in cash. This move could reshape the company’s cash f...
A major fund trimmed its LKQ position by 777,000 shares, raising questions about what this means for the stock and th...
As Rocket Lab nears a pivotal earnings print, investors are quietly growing more bullish. This piece breaks down why ...
Ford is plotting a bold move with ford's next generation electric—a scalable, low-cost EV platform designed to suppor...
Discover why savvy passive investors are turning to multifamily real estate. This guide breaks down the benefits, loa...
Franklin Templeton’s tokenization journey marks a turning point for traditional asset managers. This article breaks d...
An insider at Mirion Technologies reduced his stake by roughly $165,000 in a May 2026 move. This article explains how...
SpaceX finally faces the public market with its first earnings call after the IPO. This guide breaks down what invest...
Regulators revived a stalled pipeline, prompting questions for investors in Sable Offshore. This guide breaks down wh...
A sharp drop in Planet Labs shares sparked questions about growth, cash burn, and contract momentum. This guide break...
Anthropic's IPO is on the horizon, stirring excitement and questions for investors. This guide breaks down what to wa...
Savara investors should stay focused on how insider moves and regulatory timelines interact with a growing biotech st...